Search
mephobarbital (Mebaral)
Tradename: Mebaral. DEA-controlled substance: class 4.
Indications:
- tonic-clonic (grand-mal) seizures
- absence (petit-mal) seizures
- anxiety, apprehension [3]
Dosage:
1) 32-200 mg PO TID
2) children: 4-10 mg/kg/day PO divided BID-QID
Tabs: 32, 50, 100 mg.
Pharmacokinetics: metabolized to phenobarbital.
Adverse effects:
1) common (> 10%)
- dizziness, lightheadedness, drowsiness, "hangover"
2) less common (1-10%)
- confusion, depression, unusual excitement, nervousness, constipation, faintness, headache, nausea/vomiting, insomnia, nightmares
3) uncommon (< 1%)
- agranulocytosis, rash, exfoliative dermatitis, hallucinations, hypotension, megaloblastic anemia, Stevens-Johnson syndrome, thrombocytopenia, thrombophlebitis, respiratory depression, angioedema, dependence
Drug interactions: (see phenobarbital)
Laboratory:
- mephobarbital in hair
- mephobarbital in meconium
- mephobarbital in stool
- mephobarbital in milk
- mephobarbital in urine
Interactions
drug interactions
drug adverse effects (more general classes)
Related
phenobarbital; PB; PHB (Luminal, Barbita, Solfoton)
General
barbiturate
sedative/hypnotic (tranquilizer)
Properties
MISC-INFO: elimination route LIVER
KIDNEY
pregnancy-category D
safety in lactation ?
Database Correlations
PUBCHEM cid=8271
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Deprecated Reference